New drug combo shows promise for Hard-to-Treat breast cancer
NCT ID NCT07288359
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests a new drug called GVV858, alone or with hormone therapy, in people with advanced hormone receptor-positive, HER2-negative breast cancer and other solid tumors. The goal is to find the safest dose and see how well it works. About 205 adults whose cancer has progressed after standard treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
RECRUITINGOlomouc, 779 00, Czechia
-
Novartis Investigative Site
RECRUITINGOdense C, 5000, Denmark
-
Novartis Investigative Site
RECRUITINGJena, Thuringia, 07740, Germany
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGMilan, MI, 20162, Italy
-
Novartis Investigative Site
RECRUITINGMilan, 20141, Italy
-
Novartis Investigative Site
RECRUITINGKyoto, 6068507, Japan
-
Novartis Investigative Site
RECRUITINGSingapore, 168583, Singapore
-
Novartis Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28041, Spain
-
Novartis Investigative Site
RECRUITINGTaipei, 10002, Taiwan
-
Tennessee Oncology PLLC
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
Contact